Sigyn Therapeutics, Inc.

SIGY

Sigyn Therapeutics, Inc.

SIGY

Insider Sentiment (TTM):

Last Purchase:2017-06-23Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:N/AInstitutional Shares Owned:N/AShares Outstanding:N/AInstitutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2025-11-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Cash And Cash Equivalents At Carrying Value	0	0	0	0	0	0	0	0	0	0	0	0
Inventory Net	-	-	-	-	0	0	0	0	0	0	0	0
Assets Current
Assets Current	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Current	-	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	-	-	0	0	0	0	0	0	0	0	0	0
Finite Lived Intangible Assets Net	-	-	-	-	-	-	-	-	-	0	0	0
Operating Lease Right Of Use Asset	-	-	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	0	0	0	0	0	0	0	0	0	0	1	0
Liabilities And Stockhold…
Accounts Payable And Accrued Liabilities Current	-	-	-	1	-	-	-	0	-	-	-	-
Accounts Payable Current	1	1	1	-	1	0	1	0	0	0	0	0
Accrued Payroll Taxes Current	2	2	2	2	2	1	1	1	0	0	0	0
Liabilities Current
Liabilities Current	4	5	5	5	4	4	4	4	4	3	3	2
Short Term Borrowings	0	0	0	0	-	-	-	-	-	-	-	-
Notes Payable Current	0	2	2	2	2	2	2	2	3	3	2	2
Operating Lease Liability Current	-	-	0	0	0	0	0	0	0	0	0	0
Derivative Liabilities Current	0	-	-	-	-	-	-	-	-	-	-	-
Other Liabilities Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Noncurrent
Liabilities Noncurrent	2	-	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0
Long Term Notes Payable	2	-	-	-	-	-	-	-	-	-	-	-
Liabilities	6	5	5	5	4	4	4	4	4	3	3	2
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	-6	-5	-5	-4	-4	-4	-4	-3	-4	-3	-2	-2
Additional Paid In Capital	11	11	10	10	10	9	8	8	7	6	6	5
Retained Earnings Accumulated Deficit	-17	-17	-15	-15	-14	-13	-12	-11	-10	-9	-9	-7
Liabilities And Stockholders Equity	0	0	0	0	0	0	0	0	0	0	1	0
Unamortized Debt Issuance Expense	-	-	-	-	-	-	-	-	-	0	1	1
Debt Instrument Unamortized Discount Current	0	0	0	0	-	-	-	0	-	-	-	-
Deferred Finance Costs Current Gross	0	0	0	0	0	0	0	0	1	-	-	1
Long Term Debt Current	1	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	100	100	100	100	1,000	1,000	1,000	100	1,000	1,000	1,000	1,000
Common Stock Shares Issued	2	2	2	2	1	1	1	1	1	1	1	1
Shares Outstanding	2	2	2	2	1	1	1	1	1	1	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	-22.10%	-20.68%	-20.68%	-18.48%	-34.78%	-69.57%	-9.00%	-14.50%	-69.25%	-	-	-
2024	5.00%	5.00%	-4.00%	0.00%	0.00%	-0.87%	-24.63%	-41.67%	-40.74%	-14.94%	-33.73%	-33.73%
2023	-23.42%	-52.25%	21.62%	113.33%	86.67%	-6.00%	39.29%	-7.14%	-46.43%	0.00%	20.00%	0.00%
2022	-	-	-	-	-	-	-	-	-	-14.00%	-24.00%	-53.33%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	0.02	0.00	0.01	0.00	0.06	0.04	0.03	0.03	0.04	0.04	0.15	0.03
Quick Ratio	0.02	0.00	0.01	0.00	0.05	0.02	0.02	0.02	0.03	0.02	0.13	0.01
Working Capital	-3.90M	-5.49M	-5.08M	-4.59M	-4.01M	-3.75M	-4.10M	-3.49M	-3.65M	-3.12M	-2.42M	-1.98M
Leverage & Debt
Debt to Equity	-1.02	-1.01	-1.05	-1.05	-1.11	-1.09	-1.08	-1.09	-1.11	-1.12	-1.28	-1.17
Debt Ratio	44.65	106.06	21.24	21.86	10.18	12.47	13.44	11.60	10.23	9.41	4.55	6.72
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.01	-2.39	-2.02	-2.51	-3.15	-2.99	-2.90	-3.77	-3.46	-3.37	-3.74	-3.13
Free Cash Flow Per Share TTM	-0.58	-0.56	-0.58	-0.65	-0.56	-0.74	-0.86	-1.26	-1.54	-1.72	-2.01	-1.96
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-19.34%	3.71%	-8.77%	-19.43%	4.30%	1.44%	-0.83%	41.51%	16.09%	12.73%	11.54%	-2.49%
EPS Growth (1Y)	-36.25%	-20.02%	-30.08%	-33.47%	-9.10%	-11.24%	-22.49%	20.23%	-2.12%	-2.97%	8.15%	-5.10%
Valuation Metrics
P/E TTM	-1.87	-1.15	-2.05	-1.26	-1.83	-1.76	-1.90	-1.25	-3.23	-1.19	-1.61	-2.17
P/B TTM	-1.02	-0.81	-1.35	-0.94	-1.86	-1.77	-1.68	-1.52	-3.46	-1.42	-2.46	-3.34
Market Cap	6.02M	4.41M	6.66M	4.20M	7.30M	6.50M	6.77M	5.19M	12.39M	4.33M	5.77M	6.36M
Enterprise Value	9.47M	6.98M	9.05M	6.25M	8.92M	8.23M	9.21M	7.39M	15.27M	6.94M	7.92M	7.99M
Calculated Values
Free Cash Flow TTM	-936.43K	-900.91K	-931.27K	-872.44K	-710.11K	-910.35K	-1.06M	-1.38M	-1.71M	-1.87M	-1.93M	-1.83M
Net Debt	3.45M	2.57M	2.39M	2.05M	1.63M	1.73M	2.44M	2.20M	2.88M	2.61M	2.15M	1.63M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2017-06-23Purchase

Owner: Segelman, Joseph

Title: Chief Executive Officer

Shares: 8,500

Price/Share: $0.08

Value: $680.00

Shares Owned: 25,021,000

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2017-03-29Purchase

Owner: Segelman, Joseph

Title: CEO

Shares: 2,500

Price/Share: $0.12

Value: $300.00

Shares Owned: 25,012,500

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2016-12-19Purchase

Owner: Segelman, Joseph

Title: CEO

Shares: 5,000

Price/Share: $0.10

Value: $500.00

Shares Owned: 25,010,000

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2016-12-14Purchase

Owner: Segelman, Joseph

Title: CEO

Shares: 5,000

Price/Share: $0.10

Value: $500.00

Shares Owned: 25,005,000

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2017-06-23	Segelman, Joseph	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Purchase	8,500	0.08	$680.00	25,021,000	4/A
2017-03-29	Segelman, Joseph	Director,Officer,TenPercentOwner	CEO	Direct	Purchase	2,500	0.12	$300.00	25,012,500	4
2016-12-19	Segelman, Joseph	Director,Officer,TenPercentOwner	CEO	Direct	Purchase	5,000	0.10	$500.00	25,010,000	4
2016-12-14	Segelman, Joseph	Director,Officer,TenPercentOwner	CEO	Direct	Purchase	5,000	0.10	$500.00	25,005,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

No institutional ownership data available.

Sigyn Therapeutics, Inc. (SIGY) — SEC Financial Statements & Analysis

Sigyn Therapeutics, Inc. (SIGY) is a surgical & medical instruments & apparatus company, incorporated in DE. Sigyn Therapeutics, Inc. trades on OTC as: SIGY. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Sigyn Therapeutics, Inc. reported a Debt-to-Equity ratio of -1.02x, a Price-to-Book (P/B) ratio of -1.02x (TTM), at a market cap of $6.02M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -1.02x
P/B TTM: -1.02x
Market Cap: $6.02M

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Sigyn Therapeutics, Inc. in?

Sigyn Therapeutics, Inc. (SIGY) operates in the Surgical & Medical Instruments & Apparatus industry.

What is SIGY's market cap?

Sigyn Therapeutics, Inc. (SIGY) has a market capitalization of $6.02M as of 2025-09-30.

What exchange does SIGY trade on?

Sigyn Therapeutics, Inc. (SIGY) trades on the OTC.

Where is Sigyn Therapeutics, Inc. incorporated?

Sigyn Therapeutics, Inc. is incorporated in DE.